Climb Bio
CLYM
71 hedge funds and large institutions have $278M invested in Climb Bio in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 28 increasing their positions, 7 reducing their positions, and 7 closing their positions.
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
300% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 7
51% more funds holding
Funds holding: 47 → 71 (+24)
22% less capital invested
Capital invested by funds: $355M → $278M (-$76.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
86.25% less ownership
Funds ownership: 167.76% → 81.52% (-86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.48M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$5.16M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.76M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$12.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.77M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$4.61M |
| 4 |
Walleye Capital
New York
|
-$1.4M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$1.21M |
CLYM Hedge Fund Activity: Q3 2024 in Review
71 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2024, worth a combined $278M — down 22% from $355M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CLYM positions and 7 closed out — a net gain of 24 holders — while 28 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Deep Track Capital, cutting an estimated $12.3M.
- 71 institutional investors held Climb Bio (CLYM) as of Q3 2024, up from 47 in Q2 2024.
- Funds reported $278M of Climb Bio stock for Q3 2024, down 22% quarter-over-quarter.
- 31 funds opened new Climb Bio positions in Q3 2024 and 7 closed out, a net change of +24 holders.
- The largest Climb Bio buyer in Q3 2024 was BlackRock, an estimated $10.5M added.
- The largest Climb Bio seller in Q3 2024 was Deep Track Capital, an estimated $12.3M sold.
Based on aggregated 13F filings for Q3 2024.